Analytical Data
-
Gene name
PTGDS
- Application
-
Alternative Names
HPGDS; GSTS; H-PGDS; PDS; PGD2; PGDS; PGDS2; Glutathione S-Transferase Sigma; Glutathione-requiring prostaglandin D synthase; Prostaglandin D2 Synthase, Hematopoietic
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
O60760
-
Expression Region
Met1~Leu199
-
Molecular Weight
27kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PTGDS (Prostaglandin D2 Synthase) is an enzyme that plays a crucial role in the biosynthesis of prostaglandin D2 (PGD2), a signaling molecule involved in various physiological processes, including regulation of sleep, immune responses, and inflammatory pathways. The study of PTGDS is significant due to its implications in various diseases, such as asthma, allergies, and neurological disorders. Recent advancements in protein engineering have enabled the development of recombinant PTGDS, allowing researchers to investigate its structure-function relationships and enzymatic mechanisms in detail. By using recombinant DNA technology, scientists can produce large quantities of PTGDS for in vitro studies, offering insights into its regulatory mechanisms and potential therapeutic targets. Additionally, understanding PTGDS's role in the modulation of PGD2 could lead to novel drug design strategies aimed at mitigating its associated pathologies, thereby contributing to improved health outcomes. As the field of targeted therapies expands, recombinantly produced PTGDS may serve as a valuable tool in elucidating the complexities of prostaglandin signaling and its broader implications in human health.
